An observational study in Coronary Artery Disease, sponsored by Henan Institute of Cardiovascular Epidemiology. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Henan Institute of Cardiovascular Epidemiology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.
Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 30th largest by planned enrollment of the 218 observational ones that give a count, is one of 38 that started in 2024, is one of 219 observational ones, reaches primary completion later than 62 of the 209 other live ones, and was the 404th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:
Nanjing First Hospital, Nanjing Medical University · Sites in China
Ages 18–80
BrosMed Medical Co., Ltd · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
Beijing Inno Medicine Co., Ltd. · Sites in China, United States, Australia and 1 more country
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
543 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 25 · Phase 3 24 · Phase 4 66
First in 2000; this study’s year is marked. 38 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 307 across the 324 interventional studies, 720 across the 218 observational. Of the 187 that completed or were terminated, 24 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 543 have an industry lead sponsor. The 10 most frequent:
Henan Institute of Cardiovascular Epidemiology is the lead sponsor of 31 studies on the registry; 11 are open to participants now.
Henan Institute of Cardiovascular Epidemiology has 5 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
32 of the studies in Coronary Artery Disease with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05175274Phase 3Qingdao Central HospitalColchicine Use for Primary Prevention of Coronary Artery Disease | 2027-03-01 |
| NCT07439133Phase 3Sinotau Pharmaceutical GroupComparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR) | 2027-06 |
| NCT05638867China National Center for Cardiovascular DiseasesNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | 2026-12 |
| NCT06845410Peking Union Medical College HospitalClinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study | 2026-12 |
| NCT06917664China National Center for Cardiovascular DiseasesTreatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease | 2026-12 |
Add all 32 to your calendar (.ics) → With an account.
Among the 543 studies in Coronary Artery Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This ambiprospective observational study evaluates the long-term safety and efficacy of Paclitaxel Drug-Coated Balloon (DCB) angioplasty in approximately 20,000 patients withcoronary artery lesions in large vessels. By combining retrospective historical data with a prospective registry involving biological specimen collection, the study aims to identify key predictors of outcomes, including intravascular imaging findings, hemodynamic parameters, and biological markers. Patients will be followed longitudinally for up to 10 years to assess the durability of the treatment and the incidence of major adverse cardiovascular events (MACE).
This is a large-scale, ambiprospective (bi-directional), observational cohort study designed to evaluate the efficacy and prognostic factors of Drug-Coated Balloon (DCB) angioplasty in patients withcoronary artery lesions in large vessels. The study aims to enroll approximately 20,000 patients, comprising both a retrospective cohort (historical data) and a prospective cohort (ongoing recruitment).
The primary objective is to investigate the impact of various determinants on clinical and angiographic outcomes. Specifically, the study will analyze differences in:
Baseline Characteristics: Demographics, comorbidities, and medication history. Lesion Features: Angiographic morphology, calcification, and lesion length. Intravascular Imaging: Quantitative and qualitative analysis using Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS).
Hemodynamic Parameters: Functional assessment indices such as Quantitative Flow Ratio (QFR) or Fractional Flow Reserve (FFR).
Procedural Approaches: Pre-dilation techniques, balloon sizing ratios, and inflation duration.
Biological Specimen Collection:
For the prospective cohort, biological samples (including peripheral venous blood) will be collected at baseline. These samples will be processed to isolate serum, plasma, and DNA/RNA for biobanking. The aim is to identify potential biomarkers (e.g., inflammatory markers, genetic polymorphisms, or metabolic profiles) associated with vascular remodeling, neointimal hyperplasia, and late lumen loss following DCB treatment.
Endpoints and Follow-up:
The study is designed to assess clinical and angiographic outcomes longitudinally. Follow-up assessments will be conducted at scheduled intervals (e.g., 1 year) and will extend to very long-term follow-up (up to 10 years). This extended observation period aims to evaluate the durability of the procedure and the long-term safety profile.
Clinical Endpoints: Major Adverse Cardiovascular Events (MACE), defined as a composite of cardiac death, target vessel myocardial infarction, and target lesion revascularization.
Angiographic Endpoints: Late Lumen Loss (LLL) and Binary Restenosis Rate assessed by Quantitative Coronary Angiography (QCA) at designated angiographic follow-up windows.
This study targets adults aged 18 and over who have been diagnosed with coronary artery disease featuring native large vessel lesions and are scheduled to undergo paclitaxel drug-coated balloon angioplasty.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age:
18 years and older.
Diagnosed with coronary artery disease with native large vessel lesions confirmed by coronary angiography.
Scheduled to receive paclitaxel drug-coated balloon angioplasty.
Patients have been fully informed about the nature and purpose of the study, and have voluntarily agreed to participate, with signed informed consent.
Cardiac function classified as I-III.
Exclusion Criteria:
Known allergies to paclitaxel or any materials used in angioplasty (e.g., contrast agents).
Uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg).
Active bleeding or clotting disorders.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Target Vessel Failure (TVF)
Composite of cardiovascular death, target vessel myocardial infarction, or clinically driven target vessel revascularization, defined according to the Academic Research Consortium (ARC) criteria.
Time frame: From the index procedure through up to 10 years of follow-up
Target Lesion Revascularization (TLR)
Repeat percutaneous intervention or surgical bypass of the target lesion due to restenosis or other complications.
Time frame: From the index procedure through up to 10 years of follow-up
Target Vessel Revascularization (TVR)
Any repeat revascularization of the target vessel
Time frame: From the index procedure through up to 10 years of follow-up
Major Adverse Cardiovascular Events (MACE)
Composite of all-cause death, myocardial infarction, stroke, or any revascularization.
Time frame: From the index procedure through up to 10 years of follow-up
All-cause mortality
Death from any cause.
Time frame: From the index procedure through up to 10 years of follow-up
Late lumen loss (LLL)
Difference between post-procedural and follow-up minimal lumen diameter assessed by quantitative coronary angiography.
Time frame: At the first available follow-up coronary angiography, up to 10 years
Binary restenosis
Diameter stenosis ≥50% at follow-up angiography.
Time frame: At the first available follow-up coronary angiography, up to 10 years
Quantitative Flow Ratio (QFR)
Functional assessment of coronary physiology derived from angiography.
Time frame: Immediately after the index DCB procedure and at the first available follow-up coronary angiography, up to 10 years
Bleeding Events
Classified by BARC (Type 1-5) at 12 months.
Time frame: 12 months after the index procedure
cardiovascular death
Death due to cardiovascular causes, including death caused by acute myocardial infarction, sudden cardiac death (including unwitnessed death), heart failure, stroke, cardiovascular procedures, or cardiovascular hemorrhage, according to the Drug-Coated Balloon Academic Research Consortium (DCB-ARC) criteria.
Time frame: Up to 5 years after the index DCB procedure
Myocardial Infarction (MI)
Occurrence of myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction. Both target-vessel and non-target-vessel myocardial infarctions will be recorded.
Time frame: From the index procedure through up to 10 years of follow-up.
Target Vessel Myocardial Infarction (TV-MI)
Myocardial infarction attributable to the target vessel. This includes myocardial infarction related to the DCB-treated target lesion and myocardial infarction arising from a non-target lesion within the same target vessel.
Time frame: From the index procedure through up to 10 years of follow-up.
Ran from Oct 2024 to primary completion in Dec 2025, 14 months.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's 14 months is below that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Henan Institute of Cardiovascular Epidemiology